Sanjivani Paranteral Ltd Share Price Today - Sanjivani Paranteral Ltd Stock Price Live NSE/BSE

Sanjivani Paranteral Ltd

NSE: BSE: 531569

₹160

(-3.00%)

Tue, 05 May 2026, 11:40 pm

MTF 5xInvest in Sanjivani Paranteral Ltd with 5x Leverage Buy with MTF

Market Cap2.01B

PE Ratio24.38

Dividend0.31

Health Technology

Pharmaceuticals: Major

24.5K

Sanjivani Paranteral Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
198.51
Net Profit
8.09
P/B
7.77
Sector P/E
33.38
P/E
35.20
EV/EBITDA
25.12
Debt/Equity (Industry)
0.27
Interest Cover (Industry)
10.76
ROCE (Industry)
16.38
RONW (Industry)
14.42
ROE
10.14
ROCE
12.91
Debt/Equity
0.14
EPS (TTM)
6.78
Dividend Yield
0.30
Book Value
36.49
Interest Cover
18.54

Analysis

all

Pros

Ashwani's remuneration is about average for companies of similar size in India.
Ashwani's compensation has been consistent with company performance over the past year, both up more than 20%.
BSE:531569 is up 10% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
BSE:531569 is up 10% outperforming the market in India which returned 8% over the past month.

Cons

Unable to evaluate Sanjivani Paranteral's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Sanjivani Paranteral's dividend against the top 25% market benchmark as the company has not reported any payouts.
Sanjivani Paranteral's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Operating cash flow is negative therefore debt is not well covered.
Sanjivani Paranteral has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	31.26	31.20	31.20	28.87	28.87
FII	0	0	0	0	0
DII	6.04	6.04	6.03	6.15	6.15
Public	62.71	62.76	62.77	64.98	64.98
Government	0	0	0	0	0

Technical Analysis

RSI

50.84

MACD

-0.54

50 DMA

169.42

200 DMA

203.11

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	254.08	208.03	184.02	161.98	137.97	115.93	69.88
Fibonacci	208.03	190.44	179.57	161.98	144.39	133.52	115.93
Camarilla	172.66	168.44	164.22	161.98	155.78	151.56	147.34

Pivots Level: Classic

+92.10

254.08

+46.05

208.03

+22.03

184.02

161.98

Pivot Point

LTP: 167.50

-24.02

137.97

-46.05

115.93

-92.10

69.88

Moving Average

SMAEMA

Period

Value

10-EMA
165.81
20-EMA
166.12
30-EMA
167.01
50-EMA
170.95
100-EMA
182.10
200-EMA
199.25

Announcement Date	Purpose	Action	Ex Date
13 Feb 2026	board-meetings	Quarterly Results
14 Nov 2025	board-meetings	Quarterly Results
19 Aug 2025	dividend	Dividend - Rs. - 0.5	19 Sept 2025
12 Aug 2025	agm
27 May 2025	dividend	₹0.50 Dividend /Share	19 Sept 2025
06 Aug 2024	agm
26 Dec 2023	egm
06 Sept 2023	agm
13 Sept 2022	agm
10 Sept 2021	agm

Sanjivani Paranteral Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd

Cipla Ltd

Sanjivani Paranteral Ltd About

Sanjivani Paranteral is a research based, international pharmaceutical company that provides a wide range of high-quality product and services, at affordable prices. The core product range of the company’s products includes oral solids, small volume parenteral and sterile powder formulations.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1994

Headquarters

CEO

Ashwin Khemka

Employees

Contact

Website

http://www.sanjivani.co.in

corporate@sanjivani.co.in; info@sanjivani.co.in, s

Phone

91-22-67290900

Location

205 P N Khotari Indl Estate, LBS Marg Bhandup (West), Mumbai, Maharashtra, 400078

Year	History
2004	The company bagged an order for the supply of 3 million Units of Cephalosporin to the CIS Market. The company was incorporated and obtained Certificate of incorporation on 05/10/1004 and Certificate for Commencement of Business on 24/11/1994.
2005	The company received an order of approximately Rs 316.80 million from the Kerela Government.
2006	The company secured the bid of CMS Tender of West Bengal Government for bulk supply to all the Hospitals of West Bengal Government. The company bagged the prestigious order of Mumbai Municipal Corporation.
2007	Sanjivani Paranteral Ltd entered into rate contracts with the Defence Ministry of India for three years. The company launched a new product named SANCIDAL. The company received an initial order of Rs 5.00 Cr from the Defence Ministry.
2008	The company acquired a new pharmaceutical manufacturing plant in Uttarakhand.

Client Name	Order Side	QTY	Avg Price	Date
MONIKA GARWARE	Sell	227509	243.44	19 Feb 2025
NEXT ORBIT VENTURES FUND	Sell	200000	290	26 Aug 2024
NEXT ORBIT VENTURES FUND	Sell	100000	280.46	22 Aug 2024
SUREKHA HARAN	Sell	101034	152.7	20 Dec 2023
SUREKHA HARAN	Buy	50000	100.05	18 Sept 2023
SETU SECURITIES PVT. LTD.	Buy	50000	100.06	15 Sept 2023
SUREKHA HARAN	Buy	50000	100	12 Sept 2023
WOODSTOCK SECURITIES PRIV ATE LTD	Sell	55966	27.02	27 Mar 2023
WOODSTOCK SECURITIES PRIV ATE LTD	Sell	79292	25.94	24 Mar 2023
NEXT ORBIT VENTURES FUND	Sell	60000	32.75	20 Mar 2023

Sanjivani Paranteral Ltd News

Sanjivani Paranteral Board Meet Set for May 14, 2026

Sanjivani Paranteral's board meeting is scheduled for May 14, 2026, to consider audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026.

05 May 2026

companies

Sanjivani Paranteral Files Q4 FY26 SEBI Certificate

Sanjivani Paranteral Limited submitted its quarterly certificate under SEBI Regulation 74(5) for Q4 FY26 period ended March 31, 2026, with no dematerialization requests received during the quarter.

07 Apr 2026

companies

Sanjivani Paranteral Files Annual SEBI Disclosure

Sanjivani Paranteral Limited submitted its annual disclosure under SEBI takeover regulations, confirming no encumbrance on promoter shares during FY26.

02 Apr 2026

companies

Ashwani Khemka Boosts Stake in Sanjivani Paranteral

Managing Director Ashwani Khemka acquired 3,640 additional shares in Sanjivani Paranteral Limited through open market purchase, increasing his shareholding from 29.57% to 29.60% on March 30, 2026.

01 Apr 2026

companies

Ashwani Khemka Increases Stake in Sanjivani Paranteral

Managing Director Ashwani Khemka acquired 6,451 additional shares in Sanjivani Paranteral Limited through open market purchase, increasing his shareholding from 29.51% to 29.57% on March 27, 2026.

30 Mar 2026

companies

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800